Description
Teriflunomide, the active metabolite of leflunomide, is an immunomodulatory drug inhibiting pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase. It inhibits rapidly dividing cells, including activated T cells, and tyrosine kinase enzymes.
Synonyms
Leflunomide Impurity B; A77 1726; A771726; A77-1726; HMR1726; HMR-1726; HMR 1726; N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide; 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-beuteamide; LEF-M; Leflunomide EP Impurity B; Aubagio; (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide; Femorix
IUPAC Name
(Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide
Molecular Formula
C12H9F3N2O2
Canonical SMILES
CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O
InChI
InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
InChIKey
UTNUDOFZCWSZMS-YFHOEESVSA-N
Boiling Point
410.8±45.0°C (Predicted)
Density
1.424±0.06 g/cm3 (Predicted)
Solubility
Soluble in DMSO (Slightly), Methanol (Sparingly)
Appearance
White to Off-white Solid
Application
Anti-Inflammatory Agents, Non-Steroidal
Storage
Store at -20°C under inert atmosphere